Heparin Crisis Spurs Changes In FDA Emergency Response Policies
This article was originally published in The Tan Sheet
Executive Summary
Internal and external evaluations of FDA's handling of the heparin contamination crisis of early 2008 have led to changes in the agency's emergency response strategy and a new policy on emergency collaborations with outside experts.
You may also be interested in...
Accelerated Approval: How The Aduhelm Probes Will, And Won’t, Impact The Debate
Even as the US FDA can expect to be put through the ringer with the congressional and HHS Inspector General probes, the process could have some upsides for the agency, according to former officials who have been through such scrutiny.
Barton Attracts Support In Uphill Bid For Energy and Commerce Chair
Rep. Joe Barton pushes to regain the Energy and Commerce Committee chair against the long odds of fellow Republicans appointing him to the post that wields significant influence over FDA and the OTC drug and nutritional product industries.
Heparin Fallout Likely To Impact Supplement Ingredient Testing Exemptions
The discovery of adulterated ingredients in imported prescription drugs will likely cause increased scrutiny of supply chain operations for other segments across the food and drug industries